Vascular thrombotic events in the era of modern myeloma therapy. (19th September 2022)

• Record Type: Journal Article
• Authors: Mai, Elias Karl
• Is Part Of: British journal of haematology. Volume 199:Number 5(2022)
• Page Start: 642
• Page End: 644
• Publication Date: 2022-09-19
• Subjects: aspirin -- clinical trials -- heparin -- multiple myeloma -- thrombosis -- venous thrombosis; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.18452
• Languages: English
• ISSNs: 0007-1048

Abstract

Abstract : The treatment landscape in multiple myeloma (MM) has changed drastically in the past two decades with new treatment paradigms evolving. In this issue Sborov et al . provide the first study investigating the frequency, severity, onset of vascular thrombotic events (VTEs) and use of prophylactic therapies in a trial applying a contemporary myeloma treatment protocol and highlight that prevention of VTEs needs to be revisited in the era of modern myeloma treatment. Commentary on: Sborov et al. Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study. Br J Haematol. 2022;199:355–365.